RT Journal Article
SR Electronic
T1 The impact of gastric acid suppression on the developing intestinal microbiome of a child
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.21.21268064
DO 10.1101/2021.12.21.21268064
A1 Spurr, Andrew
A1 Zhu, Wei
A1 Wong, Wendy S. W.
A1 Diez, Bernadette
A1 Leibowitz, Ian
A1 Louis-Jacques, Otto
A1 Vilboux, Thierry
A1 Niederhuber, John
A1 Levy, Shira L
A1 Hourigan, Suchitra K
YR 2021
UL http://medrxiv.org/content/early/2021/12/22/2021.12.21.21268064.abstract
AB Gastric acid suppressing medications have been associated with an increased risk of Clostridioides difficile (C. difficile) infection, hypothesized to be due to underlying intestinal microbiome changes. Our goal is to characterize these changes in children as their microbiome is undergoing critical development. Our study included 5 children (< 3 years old) who were started on clinically indicated gastric acid suppression and 15 healthy age-matched controls. Stool samples were collected before and after 2 months of treatment. We analyzed the microbiome using 16S rRNA sequencing. Quantitative-PCR was used to detect C. difficile toxins. Subjects and controls had similar alpha and beta diversity. We found no significant change in alpha or beta diversity of subjects after treatment. C. difficile toxins were not found and there was no increase in C. difficile carriage after treatment. A significant increase in Lactobacillus was found after treatment, which has been associated with C. difficile in adults.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Child Health and Human Development under Award Number [grant number K23HD099240] and the Inova Research Seed GrantAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Inova Health System gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors